BioTuesdays

Category - Markets

Markets

Analysts start Sonendo at buy, OW

Analyst for Stifel and Piper Sandler initiated coverage of Sonendo (NYSE:SONX) with “buy” and “overweight” ratings and prices targets of $16 and $17, respectively. The stock closed at $10.55 on Nov. 22. Sonendo is a...

November 23, 2021
Reneo Therapeutics
Markets

Ladenburg starts Reneo Pharma at buy; PT $45

Ladenburg Thalmann initiated coverage of Reneo Pharmaceuticals (NASDAQ:RPHM) with a “buy” rating and price target of $45. The stock closed at $7.99 on Nov. 19. Reneo’s clinical stage asset, REN001 is in development for...

November 22, 2021
Lensar
Markets

BTIG starts LENSAR at buy; PT $15

BTIG launched coverage of LENSAR (NASDAQ:LNSR) with a “buy” rating and $15 price target. The stock closed at $7.10 on Nov. 19. LENSAR is a small-cap technology play on the fast growing laser cataract surgery market. By...

November 22, 2021
Foghorn Therapeutics
Markets

HCW starts Foghorn Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Foghorn Therapeutics (NASDAQ:FHTX) with a “buy” rating and price target of $25. The stock closed at $13.68 on Nov. 19. Foghorn is a leader in the field of chromatin biology. The...

November 22, 2021
Minerva Surgical
Markets

Analysts start Minerva Surgical at OW, OP; PT $17

Piper Sandler and SVB Leerink launched coverage of Minerva Surgical (NASDAQ:UTRS) with “overweight” and “outperform” ratings, respectively, and price targets of $17. The stock closed at $9.62 on Nov. 15. Minerva, which...

November 16, 2021
CytomX
Markets

BTIG starts CytomX Therapeutics at buy; PT $16

BTIG initiated coverage of CytomX Therapeutics (NASDAQ:CTMX) with a “buy” rating and price target of $16. The stock closed at $7.02 on Nov. 12. CytomX is a clinical-stage biotechnology company focused on developing...

November 15, 2021
Acutes-Medical-Logo
Markets

Analysts cut Acutus Medical PT to $8 and $10

Analysts for BTIG and Canaccord Genuity reduced their price targets for Acutus Medical (NASDAQ:AFIB) to $8 from $20 and to $10 from $18, respectively, but maintain their “buy” ratings, after the company reported third...

November 12, 2021